Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
An Open-Label Single-Arm Phase 1 Study Evaluating Safety of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
Sponsor: Incyte Corporation
Listed as NCT03497273, this PHASE1 trial focuses on Acute Graft-versus-host Disease and remains completed. Sponsored by Incyte Corporation, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jul 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Nov 2018 — Jul 2019 [monthly]
Recruiting PHASE1
-
May 2018 — Nov 2018 [monthly]
Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anjo-Shi, Japan , Chūōku, Japan , Isehara-Shi, Japan , Kagoshima, Japan , Kumamoto, Japan , Minatoku, Japan , Nagaizumi-cho, Japan , Nagoya, Japan , Nishinomiya-Shi, Japan , Okayama, Japan and 6 more locations